Quest Diagnostics
794 hedge funds and large institutions have $12B invested in Quest Diagnostics in 2023 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 230 increasing their positions, 337 reducing their positions, and 82 closing their positions.
233% more call options, than puts
Call options by funds: $132M | Put options by funds: $39.7M
1.19% less ownership
Funds ownership: 88.92% → 87.73% (-1.2%)
3% less funds holding
Funds holding: 819 → 794 (-25)
14% less capital invested
Capital invested by funds: $14B → $12B (-$1.98B)
15% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 82
32% less repeat investments, than reductions
Existing positions increased: 230 | Existing positions reduced: 337
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$90.7M |
| 2 |
JP Morgan Chase
New York
|
+$71.7M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$51.7M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$44.5M |
| 5 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$129M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$74.4M |
| 3 |
AM
AGF Management
Toronto,
Ontario, Canada
|
-$64.5M |
| 4 |
BlackRock
New York
|
-$47.4M |
| 5 |
Amundi
Paris,
France
|
-$40.5M |
DGX Hedge Fund Activity: Q3 2023 in Review
794 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q3 2023, worth a combined $12B — down 14% from $14B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of DGX and 70 opened new positions — a net loss of 12 holders — while 337 trimmed existing stakes and 230 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $90.7M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $129M sold.
- 794 institutional investors held Quest Diagnostics (DGX) as of Q3 2023, down from 819 in Q2 2023.
- Funds reported $12B of Quest Diagnostics stock for Q3 2023, down 14% quarter-over-quarter.
- 70 funds opened new Quest Diagnostics positions in Q3 2023 and 82 closed out, a net change of -12 holders.
- The largest Quest Diagnostics buyer in Q3 2023 was T. Rowe Price Associates, an estimated $90.7M added.
- The largest Quest Diagnostics seller in Q3 2023 was Point72 Asset Management, an estimated $129M sold.
Based on aggregated 13F filings for Q3 2023.